AUG 12, 2020 8:50 AM PDT

Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer

WRITTEN BY: Jasper Cantrell

Since the 1940s, chemotherapy has been a primary treatment option for cancer. The late 20th century brought a new type of cancer treatment, immunotherapies. These immunotherapies enhance or suppress certain aspects of the immune system to assist in the termination of cancer.

Since then, there have been several immunotherapy drugs and immunotherapy technologies developed every year. Two such drugs are nivolumab and pembrolizumab. Both are FDA approved for the treatment of non-small cell carcinomas (among others) and block PD-1 (programmed cell death) mediated silencing of the immune response against cancer. This interaction allows the immune system to recognize cancer cells and target them for destruction. 

A team from the Chinese PLA General Hospital in China noticed a gap in the data comparing the two first-line treatments for non-small cell carcinomas. Some clinical trials suggest one is better than the other, but the current standard of care is to treat patients with either nivolumab or pembrolizumab. The team decided to investigate the overall response rate and progression-free survival of non-small cell carcinoma patients at their hospital and identify if one is more effective than the other.

Analyses of patient treatment data for cancer tend to be complex, as many go through second rounds of treatment, so comparisons like this one tend to be challenging. However, pembrolizumab had a slight but clear advantage in overall response rate, while nivolumab had a slight edge in progression-free survival as second-line therapy. Neither showed a clear strength over the other in most cases, however.

These results validate that the current standard treatment of choosing either nivolumab or pembrolizumab, as neither was significantly better in most areas. Many new nivolumab trials focus on its effectiveness as a combination therapy, which may point to it having a strong supportive role. Both drugs target the same molecule, so it stands to reason that they would both elicit similar effects as a stand-alone therapy.

The study concludes, “According to our comparisons, pembrolizumab and nivolumab demonstrated similar survival benefits in patients with recurrent or advanced NSCLC in various clinical settings. Therefore, our study may support the current clinical practice of choosing either drug based on patient and clinician preferences.”  

Sources: Nature Scientific Reports, Memorial Sloan Kettering

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 11, 2020
Cell & Molecular Biology
Visualizing a Tumor Suppressor in Action
NOV 11, 2020
Visualizing a Tumor Suppressor in Action
Many types of cells in our bodies are short-lived and need to be replenished. Cell division has to be carefully controll ...
NOV 24, 2020
Clinical & Molecular DX
Young Inventor Creates Award-winning At-home Cancer Diagnostic
NOV 24, 2020
Young Inventor Creates Award-winning At-home Cancer Diagnostic
Getting a breast cancer diagnosis often means having to endure multiple tests, including some painful and invasive proce ...
DEC 01, 2020
Cancer
The price tag of prostate cancer treatment
DEC 01, 2020
The price tag of prostate cancer treatment
New research published in The Journal of Urology from the Official Journal of the American Urological Association&n ...
JAN 05, 2021
Cancer
Two gene expression subtypes identified in peritoneal carcinomatosis cells
JAN 05, 2021
Two gene expression subtypes identified in peritoneal carcinomatosis cells
New research published in Nature Medicine finds two subtypes of gene expression in peritoneal carcinomatosis (PC) that c ...
JAN 12, 2021
Clinical & Molecular DX
Portable Sequencer Ensures All the Cancer Cells Are Gone
JAN 12, 2021
Portable Sequencer Ensures All the Cancer Cells Are Gone
Surgeons remove a tumor from the abdominal cavity of a patient. But how can they be certain that all the cancer cells we ...
Loading Comments...